Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

METOLAZONE FOR SYSTEM SUITABILITY CRS (10 MG)

METOLAZONE FOR SYSTEM SUITABILITY CRS (10 MG)

17560-51-9

DISCOVER
MOXIFLOXACIN HYDROCHLORIDE CRS (120 MG)

MOXIFLOXACIN HYDROCHLORIDE CRS (120 MG)

186826-86-8

DISCOVER
THIORIDAZINE CRS (10 MG)

THIORIDAZINE CRS (10 MG)

50-52-2

DISCOVER
MIRTAZAPINE CRS (10 MG)

MIRTAZAPINE CRS (10 MG)

61337-67-5

DISCOVER
RITONAVIR FOR PEAK IDENTIFICATION CRS (10 MG)

RITONAVIR FOR PEAK IDENTIFICATION CRS (10 MG)

155213-67-5

DISCOVER
ADRENALINE TARTRATE WITH IMPURITY A CRS (15 MG)

ADRENALINE TARTRATE WITH IMPURITY A CRS (15 MG)

51-42-3

DISCOVER
FLUPHENAZINE IMPURITY MIXTURECRS (0.07 MG)

FLUPHENAZINE IMPURITY MIXTURECRS (0.07 MG)

NA

DISCOVER
OXITROPIUM BROMIDE CRS (50 MG)

OXITROPIUM BROMIDE CRS (50 MG)

30286-75-0

DISCOVER
HYDROCODONE  FOR PEAK IDENTIFICATION CRS - * NARC (10 MG)

HYDROCODONE FOR PEAK IDENTIFICATION CRS - * NARC (10 MG)

NA

DISCOVER
SOMATROPIN/ DESAMIDOSOMATROPIN RESOLUTION MIXTURE CRS (3 MG)

SOMATROPIN/ DESAMIDOSOMATROPIN RESOLUTION MIXTURE CRS (3 MG)

NA

DISCOVER
EQUINE INFLUENZA SUBTYPE 2 AMERICAN-LIKE/SOUTH AFRICA/4/03 H

EQUINE INFLUENZA SUBTYPE 2 AMERICAN-LIKE/SOUTH AFRICA/4/03 H

NA

DISCOVER
OXITROPIUM BROMIDE IMPURITY DCRS (10 MG)

OXITROPIUM BROMIDE IMPURITY DCRS (10 MG)

95778-01-1

DISCOVER